Trial Profile
Phase II study with cetuximab, irinotecan and sunitinib (CIS) for patients with treatment resistant colorectal cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Mar 2017
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Irinotecan (Primary) ; Sunitinib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Mar 2017 New trial record